Integra LifeSciences announced the controlled market release of the Integra Expandable Interbody System in the United States.
The system received 510(k) clearance from the U.S. Food and Drug Administration earlier this year, and it is intended for spinal fusion procedures at one or two contiguous levels (L2-S1) in adult patients with degenerative disc disease. The system aims to minimize the amount of implant insertion forces while achieving the patient-specific anatomical fit needed for proper treatment.
"We are very excited to introduce our first expandable interbody device," said Mark Augusti, corporate vice president and president of orthopedics and tissue technologies. "This addition to our portfolio will cater to a vast group of spine surgeons performing posterior and transforaminal interbody fusions, including minimally invasive procedures. And with an in situ height expansion, the anatomical fit is tailored for each individual patient."
More articles on devices:
Stryker Spine to launch ALIF technology at NASS
Integra LifeSciences introduces demineralized bone matrix strip implants for spine fusion
K2M's CAPRI Corpectomy Cage System receives FDA clearance